NCE-1 Intelligence & Market Opportunity

Inluriyo

Imlunestrant

Anticancer

Oral Tablet

Inluriyo is an oral selective estrogen receptor degrader (SERD) indicated for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. It degrades estrogen receptors to block tumor growth, offering a convenient daily oral option.

Approval Date

25-Sep-25

NCE-1 Date

25-Sep-29

NCE Date

25-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

1.5786

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

137

2027

257

2028

435

2029

619

2030

825

2031

1005

2032

1166

Molecule profile

Details & specifications

Molecule

Imlunestrant

Innovator

ELI LILLY AND COMPANY

Dosage Form

Oral Tablet

Strength

200 mg

Therapeutic Category

Anticancer

Usage

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.